BANK VONTOBEL/CALL/NOVO NORDISK ADR B/145/0.1/21.03.25 Share Price

Warrant

DE000VD3N4W2

Real-time Bid/Ask 05:21:11 27/06/2024 pm IST
1.71 EUR / 1.72 EUR -6.28% Intraday chart for BANK VONTOBEL/CALL/NOVO NORDISK ADR B/145/0.1/21.03.25
Current month+61.95%
1 month+41.86%
Date Price Change
27/24/27 1.77 -3.28%
26/24/26 1.83 +12.27%
25/24/25 1.63 +1.24%
24/24/24 1.61 +3.21%
21/24/21 1.56 -2.50%

Delayed Quote Börse Stuttgart

Last update June 27, 2024 at 12:01 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
IssuerLogo Issuer Vontobel Vontobel
WKN VD3N4W
ISINDE000VD3N4W2
Date issued 08/04/2024
Strike 145 $
Maturity 21/03/2025 (267 Days)
Parity 10 : 1
Emission price 1.09
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.83
Lowest since issue 0.91
Delta0.59x
Omega 4.654
Premium13.62x
Gearing7.87x
Moneyness 0.9908
Difference Strike 1.33 $
Difference Strike %+0.92%
Spread 0.01
Spread %0.58%
Theoretical value 1.705
Implied Volatility 33.95 %
Total Loss Probability 52.12 %
Intrinsic value 0.000000
Present value 1.705
Break even 163.25 €
Theta-0.03x
Vega0.04x
Rho0.05x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007 DKK
Average target price
937.9 DKK
Spread / Average Target
-6.86%
Consensus